Editorial: Anti-tnf treatment in crohn's disease: Toward tailored therapy

American Journal of Gastroenterology

Volumn 105, Issue 5, 2010, Pages 1140-1141

  D'Haens, Geert ^a,b  

^a IMELDA HOSPITAL   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CHIMERIC ANTIBODY; HYDROCORTISONE; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIIDIOTYPIC ANTIBODY; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC REACTION; CROHN DISEASE; HUMAN; PRIORITY JOURNAL; REMISSION; REVIEW; TREATMENT FAILURE; TREATMENT RESPONSE; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG RESISTANCE; FEMALE; IMMUNOLOGY; MALE; NOTE; PROGNOSIS; RISK ASSESSMENT; TREATMENT OUTCOME;

ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; CROHN DISEASE; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE; FEMALE; HUMANS; MALE; PROGNOSIS; RISK ASSESSMENT; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77951966434     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2010.15     Document Type: Review

References (15)

1. Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infl iximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-1549
2. Colombel JF, Sandborn WJ, Rutgeerts P et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65.
3. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al., PRECISE 2 Study Investigators. Maintenance therapy with certolizumab pegol for Crohn's disease. New Engl J Med 2007; 357: 239-250
4. Sands BE, Anderson FH, Bernstein CN et al. Infl iximab maintenance therapy for fi stulizing Crohn's disease. N Engl J Med 2004; 350: 876-885
5. Colombel JF, Schwartz DA, Sandborn WJ et al. Adalimumab for the treatment of fi stulas in patients with Crohn's disease. Gut 2009; 58: 940-948
6. Rutgeerts P, Diamond RH, Bala M et al. Scheduled maintenance treatment with infl iximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 2006; 63: 433-442
7. D'Haens G, Baert F, van Assche G et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008; 371: 660-667
8. Schnitzler F, Fidder H, Ferrante M et al. Long-term outcome of treatment with infl iximab in 614 patients with Crohn's disease: results from a singlecentre cohort. Gut 2009; 58: 492-500.
9. Baert F, Noman M, Vermeire S et al. Infl uence of immunogenicity on the long-term effi cacy of infl iximab in Crohn's disease. N Engl J Med 2003; 348: 601-608
10. Hanauer SB, Wagner CL, Bala M et al. Incidence and importance of antibody responses to infl iximab aft er maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004; 2: 542-553
11. Vermeire S, Noman M, Van Assche G et al. Eff ectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infl iximab in Crohn's disease. Gut 2007; 56: 1226-1231
12. Farrell RJ, Alsahli M, Jeen YT et al. Intravenous hydrocortisone premedication reduces antibodies to infl iximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003; 124: 917-924
13. Maser EA, Villela R, Silverberg MS et al. Association of trough serum infl iximab to clinical outcome aft er scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006; 4: 1248-1254
14. Colombel JF, Rutgeerts P, Reinisch W et al. SONIC: a randomized, double blind, controlled trial comparing infl iximab and infl iximab plus azathioprine to azathioprine in patients with Crohn's disease na ï ve to immunomodulators and biologic therapy. Gut 2008; 57 (Suppl II): A1.
15. Afif WA, Loftus EV, Faubion WA et al. Clinical utility of measuring infl iximab and human anti-chimeric antibody concentrations in patients with infl ammatory bowel disease. Am J Gastroenterol 2010; 105:1133-1139